Breast Cancer Clinical Trial
Official title:
A Trial Assessing the Effect of Simvastatin on the Pharmacokinetics of Anastrozole
Verified date | May 2013 |
Source | Sidney Kimmel Comprehensive Cancer Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Federal Government |
Study type | Interventional |
RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing,
or coming back. The use of simvastatin and anastrozole may stop cancer from forming,
growing, or coming back in patients with invasive breast cancer, ductal carcinoma in situ,
or a high risk of breast cancer.
PURPOSE: This phase II trial is studying how well giving simvastatin together with
anastrozole works in treating postmenopausal women with invasive breast cancer, ductal
carcinoma in situ, or a high risk of breast cancer.
Status | Completed |
Enrollment | 11 |
Est. completion date | November 2011 |
Est. primary completion date | October 2008 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility |
DISEASE CHARACTERISTICS: - Meets any of the following criteria: - History of invasive breast cancer - History of ductal carcinoma in situ - At high risk for breast cancer, defined as being on anastrozole for chemoprevention of breast cancer - Receiving anastrozole for = 30 days as adjuvant breast cancer treatment or for prevention of breast cancer - No active breast cancer with known metastatic involvement - Hormone receptor status not specified PATIENT CHARACTERISTICS: - Female - Postmenopausal - ECOG performance status 0-2 - AST and ALT = 3 times upper limit of normal - Creatinine clearance = 30 mL/min - No active liver disease - No prior hypersensitivity to any HMG-CoA reductase inhibitor or any of its components - No daily alcohol use of > 3 standard drinks/day - A standard drink is defined as 10 g of alcohol, which is equivalent to 285 mL of beer, 530 mL of light beer, 100 mL of wine, or 30 mL of liquor PRIOR CONCURRENT THERAPY: - See Disease Characteristics - No cholesterol-lowering drug, including a statin, within the past 3 months - No selective estrogen receptor modulator (SERM) within the past 3 months - No other hormone therapy within the past 3 months - No prior estrogen and/or progesterone hormone replacement therapy that lasted for = 5 years - Vaginal estrogen preparations allowed - No other concurrent statin or cholesterol-lowering drug - No other concurrent SERM - No other concurrent hormone therapy - No other concurrent investigational drugs - No concurrent CYP3A4 inhibitors, including itraconazole, ketoconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, nefazodone, or cyclosporine - No concurrent chemotherapy or biological agents - No concurrent daily grapefruit juice > 8 oz/day - No other concurrent anticancer agents or therapies |
Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Baltimore | Maryland |
Lead Sponsor | Collaborator |
---|---|
Sidney Kimmel Comprehensive Cancer Center | National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Blood Concentrations | The change in blood concentrations of anastrozole at baseline and 14 days was measured. | Baseline and 14 days | No |
Secondary | Change in Serum Estradiol Levels | The change in serum concentrations of estradiol at baseline and 14 days was measured. | Baseline and 14 days | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A |